Inactive Instrument

Eurofarma Laboratórios S.A.

Equities

EUFA3

BREUFAACNOR4

Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 26, 2024 at 07:09 pm

Eurofarma Laboratórios S.A. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was BRL 2,539.7 million compared to BRL 2,138.2 million a year ago. Net income was BRL 227.5 million compared to BRL 260 million a year ago.

Basic earnings per share from continuing operations was BRL 0.6515 compared to BRL 0.9463 a year ago. Diluted earnings per share from continuing operations was BRL 0.6515 compared to BRL 0.9463 a year ago.

Latest news about Eurofarma Laboratórios S.A.

Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Eurofarma Laboratórios S.A. acquired Genfar S.A. from Sanofi.	23-09-28	CI
Abcuro, Inc. announced that it has received $155 million in funding from a group of investors	23-08-16	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Abcuro, Inc. announced that it expects to receive $199.522752 million in funding from Redmile Group, LLC, and other investors	23-08-10	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-26	CI
Eurofarma Laboratórios S.A. agreed to acquire Genfar S.A. from Sanofi for approximately ?300 million.	23-03-07	CI
Eurofarma Laboratórios S.A. acquired Laboratório Canonne for BRL 725 million.	22-12-14	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-14	CI
Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Pfizer Inc. and BioNTech SE Announce Collaboration with Eurofarma Laboratórios SA to Manufacture COVID-19 Vaccine Doses for Latin America	21-08-26	CI
Eurofarma Laboratórios S.A. cancelled the acquisition of a portfolio of 12 products in Latin America from Hypera S.A..	21-03-16	CI
Eurofarma Laboratórios S.A. entered into agreement to acquire A portfolio of 12 products in Latin America from Hypera S.A. for approximately $160 million.	20-03-16	CI
Biotoscana Confirms Divestiture Negotiations	19-10-09	CI
Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries Through Extended Agreement with Eurofarma Laboratórios	17-09-26	CI
Eurofarma Laboratórios S.A. acquired factory in Argentina of Sanofi.	15-09-17	CI
Melinta Therapeutics, Inc. Partners with Eurofarma Laboratorios S.A	15-01-11	CI
Melinta Therapeutics, Inc. announced that it has received $15 million in funding from Eurofarma Laboratórios S.A.	15-01-07	CI
Eurofarma Laboratorios Ltda. acquired Laboratorios Laprin, S.A.	13-07-04	CI

Chart Eurofarma Laboratórios S.A.

Duration

Period

More charts

Company Profile

Sector

More about the company